Plenty Of Room For More Obesity Drugs, Says Boehringer, As Survodutide Enters Phase III

 
• By Andrew McConaghie
  
Dawn over the Pharmalogical Research building at Biberach, Germany
Boehringer Ingelheim's R&D center in Biberach, Germany. • Source: Boehringer Ingelheim
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D